MidWest Drug Development Conference
ONLINE EVENT | Oct. 4-5, 2021
2021-10-04 08:00:00
Register!
Downloads
  • 2021 Program
  • Flyer
  • 2021 Schedule
  • 2019 Program
  • 2018 Program
  • Map & Other Info (Coming soon!)
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact

Novel antiviral therapeutics target SARS-CoV-2 infections

University of Kansas

Remdesivir is currently the only FDA-approved drug for treating COVID-19. While remdesivir improves recovery time, it does not significantly reduce death rates in hospitalized adults. Researchers at the University of Kansas have produced novel antivirals that shows promise as a COVID-19 treatment.

The new antivirals target the conserved and essential RNA sequences in the SARS-CoV-2 viral genome. Specifically, the antivirals selectively bind to RNA secondary structures close to the start codon region in the viral genome, thereby inhibiting viral replication of SARS-CoV-2. In addition to their use as single agent inhibitors of SARS-CoV-2 replication, the antivirals can also be part of a bifunctional small molecule. A bifunctional small molecule typically includes a “guide arm” and an “effector arm.” The new antivirals act as the guide arm that binds to SARS-CoV-2 in order to target the effector arm to the virus, which ultimately results in enzymatic degradation of the virus. Accordingly, these novel antivirals can inhibit viral replication of SARS-CoV-2 and degrade the SARS-CoV-2 virus when used as part of a bifunctional small molecule.

Most drugs currently contemplated for treatment of COVID-19 target viral proteins. For example, remdesivir inhibits the SARS-CoV RNA-dependent RNA polymerase. The antivirals of the present technology target the RNA structural elements in the viral genome instead of the viral proteins of SARS-CoV-2. Accordingly, they can synergistically inhibit viral replication with drugs that target viral proteins, including remdesivir, thereby improving outcomes in COVID-19 patients compared to those treated with remdesivir alone.

Logo

MIDWEST DRUG DEVELOPMENT CONFERENCE
Bringing together industry and the best university drug development researchers in the Midwest
An Online Event
Oct. 4-5, 2021

Latest News
  • Presentation schedule set for 2021 September 21, 2021
  • MWDD moves to a virtual event in 2021 August 17, 2021
  • Sponsorship, presentation slots nearly full July 29, 2021
  • Registrations are now open for 2021 March 25, 2021
Twitter Hightlights
  • Today's the day!
    491 days ago
  • Schedule is set for the 2021 MidWest Drug Development Conference. Register today! https://t.co/5SvzL4EhuV
    504 days ago
  • No surprise to see some incredible innovations out of @UWMadison that could change drug delivery approaches, cancer… https://t.co/h90yfHwC5k
    505 days ago

Follow us! @DrugMw